Aplastic anemia and severe pancytopenia during treatment with peg-interferon,ribavirin and telaprevir for chronic hepatitis C

作     者：Sabela Lens Jose L Calleja Ana Campillo Jose A Carrion Teresa Broquetas Christie Perello Juan de la Revilla Zoe Marino Maria-Carlota Londono Jose M Sanchez-Tapias Alvaro Urbano-Ispizua Xavier Forns 

作者机构：Liver UnitHospital ClinicIDIBAPSCIBERehd08036 BarcelonaSpain Liver UnitHospital Puerta del HierroIDIPHIMCIBERehd28222 MajadahondaMadridSpain Gastroenterology DepartmentHospital Reina Sofia31500 TudelaNavarraSpain Liver UnitHospital Del MarIMIMCIBERehd08003 BarcelonaSpain Hematology UnitHospital Clinic08036 BarcelonaSpain 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第17期

页      面：5421-5426页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：(in part)Instituto de Salud Carlos III(PI11/01907),Ministerio de Economia y Competitividad,co-funded by Fondo Europeo de Desarrollo Regional,Union Europea,Una manera de hacer Europa Roche Organ Transplantation Research Foundation(ROTRF,CI:442035057)(all to Forns X) 

主　　题：Aplastic anemia Hepatitis C Telaprevir Interferon Protease inhibitors 

摘      要：Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and *** due to myelotoxicity caused by these drugs may occur,but severe hematological abnormalities or aplastic anemia(AA) have not been *** collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in *** 142 cirrhotic patients receiving treatment,7 cases of severe pancytopenia(5%) were identified and three were consistent with the diagnosis of *** age was 59 years,five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver *** pancytopenia was diagnosed a median of 10 wk after the initiation of *** patients had pre-treatment hematological abnormalities related to *** six patients,antiviral treatment was interrupted at the onset of hematological *** patients died due to septic complications and one patient due to acute alveolar *** remaining patients *** pancytopenia and especially AA,are not rare during triple therapy with telaprevir in patients with advanced liver *** monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications.